Calciduran Vit. D3

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Calciduran Vit. D3

Property Description
Active Ingredients Calcium Carbonate, Dihydrotachysterol (DHT)
Form Oral Tablet
Pharmacological Class Vitamin D and analogues, Calcium Supplement
Common Use Maintaining bone density and mineral balance
Origin Mineral source (Calcium) and Synthetic Analogue (DHT)

Calciduran Vit. D3 is a foundational fixed-dose combination oral preparation classified as an antihypocalcemic agent and a specialized nutritional supplement. It is designed to address combined deficiencies in essential minerals and vitamins critical for maintaining bone density and stable calcium metabolism. The preparation belongs to the broader pharmacological class of Vitamin D and analogues combined with a Calcium supplement.


Composition and Classification of Calciduran Vit. D3

The medicine is defined by its two active ingredients: Calcium Carbonate and Dihydrotachysterol (DHT). Calcium Carbonate acts as the source of elemental calcium, the mineral essential for skeletal structure, muscle contraction, and nerve function. The second component, Dihydrotachysterol, is a synthetic secosteroid and an effective Vitamin D analogue that plays a crucial role in mineral regulation.

Dihydrotachysterol differs from natural Cholecalciferol (Vitamin D3) because it is chemically modified to be more direct-acting, requiring fewer metabolic steps to become fully active. This fixed-dose combination—offered as an oral tablet—is clinically recognized for its targeted approach to calcium supplementation, distinguishing it from single-ingredient products.


General Purpose: Supporting Mineral Homeostasis

The overall purpose of Calciduran Vit. D3 is to ensure the effective management of mineral metabolism in the body. By supplying the mineral via Calcium Carbonate and optimizing its utilization via the Dihydrotachysterol analogue, the product aims to prevent or correct imbalances. This combined approach is generally used to conserve bone density and maintain stable calcium and phosphorus concentrations necessary for overall biological function. These systems rely on the adequate availability of calcium and Vitamin D to regulate bone health and prevent deficiency.

Advertisements

What side effects are possible with Calciduran Vit. D3?

Possible Side Effects and Safety Information

The official safety profile for Calciduran Vit. D3, a combination of Calcium Carbonate and a Vitamin D analogue, is defined by the potential effects on mineral balance, primarily due to the risk of calcium accumulation. Regulatory documents classify adverse reactions by frequency and the body system affected.

Classification Adverse Reactions (Examples)
Common Hypercalcaemia (high blood calcium), Hypercalciuria (high urine calcium)
Uncommon Gastrointestinal effects (e.g., constipation, flatulence, nausea)
Rare Hypersensitivity reactions (e.g., rash, pruritus)

Serious adverse reactions are officially documented as rare but significant consequences of uncontrolled calcium elevation, including severe Hypercalcaemia and Nephrocalcinosis (calcification of the kidneys). These events are typically linked to long-term use or excessive dosage, a pattern explicitly noted in regulatory texts.

The safety information includes population-specific considerations and restrictions. The medicine is formally contraindicated (should not be used) in patients with pre-existing conditions like Hypercalcaemia, D-Hypervitaminosis, Nephrocalcinosis, or severe renal impairment due to the high risk of serious adverse reactions. The official label also highlights the need for routine monitoring of serum and urinary calcium levels, particularly in older adults and those with renal impairment, to prevent the documented risks associated with sustained high calcium concentrations.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Calciduran Vit. D3, a fixed-dose combination of Calcium Carbonate and the Vitamin D analogue Dihydrotachysterol (DHT), is officially documented to result in hypercalcemia (excessive blood calcium levels).

Documented Overdose Presentations

Domain Official Regulatory Statement
Documented overdose presentations The primary presentation is hypercalcemia, manifesting with clinical signs such as nausea, vomiting, constipation, polyuria (increased urination), polydipsia (increased thirst), headache, and anorexia (loss of appetite).
Physiological systems affected Officially documented severe effects involve the renal system (potential for renal impairment) and the cardiovascular system (potential for cardiac arrhythmias).
Population-specific overdose notes Regulatory labeling specifies that patients with pre-existing renal impairment are at an increased risk for severe and prolonged hypercalcemia following an overdose.

Emergency Actions Mandated by Regulators

  • Seek immediate medical attention or contact emergency services upon the manifestation of any sign or symptom of overdose, particularly persistent gastrointestinal issues or severe headache.
  • The mandated action is the immediate cessation of the drug and all other calcium/Vitamin D sources.
  • Management of overdose is officially defined as symptomatic and supportive treatment; no specific antidote is known.
  • Treatment involves procedures such as aggressive intravenous rehydration and hospital monitoring to manage the hypercalcemia and assess renal function.

The official profile establishes hypercalcemia and its associated severe organ risks as the key toxicity of the combined agents. This potential for serious renal and cardiovascular outcomes serves as the sole basis for the mandatory requirement to seek immediate medical attention as described in regulatory documents.

Advertisements

Therapeutic Uses of Calciduran Vit. D3

What Calciduran Vit. D3 Treats: Main Uses and Benefits

Calciduran Vit. D3 is a combined supplement used in situations involving certain distressing symptoms related to deficiency and bone health. Its application is relevant for managing specific deficiencies and conditions that impact bone health.

Supporting Bone Health and Easing Deficiency Symptoms

This medication is applied across domains where additional symptomatic support is needed, primarily addressing symptom clusters that may become intense or disruptive related to low bone mineral density and systemic imbalance. It provides essential support, which contributes to improved day-to-day comfort and assists with maintaining functional stability.

Quick Fact: Relief for Symptoms Related to Bone Health

The product is commonly used to help with conditions characterized by periods of heightened symptoms, offering symptomatic relief when symptoms interfere with routine activities.

Complementing Specific Osteoporosis Treatments

Calciduran Vit. D3 is often used when symptoms intensify and supportive relief is needed, particularly as an adjunct to specific medical treatments for conditions involving episodic or fluctuating manifestations, like osteoporosis. It helps maintain a sense of stability when symptoms are more noticeable, contributing to easing the overall symptom load during difficult episodes.

Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Calciduran Vit. D3?

Eligibility for Calciduran Vit. D3 (Calcium Carbonate and Colecalciferol) is determined by official regulatory labeling, focusing on specific health conditions and age groups.

Populations with Absolute Contraindications

The medicine is contraindicated and must not be used by patients with:

  • Hypersensitivity to the active substances or excipients.
  • Hypercalcaemia (high blood calcium levels) or Hypercalciuria (high urine calcium levels).
  • Hypervitaminosis D (excessive Vitamin D levels).
  • Severe Renal Impairment or a history of Nephrolithiasis (kidney stones).

Age and Conditional Eligibility

Adults and the Elderly are the established populations for this product. Use in the Paediatric Population (children and adolescents, generally under 12 years of age) is typically not recommended by regulatory bodies.

Pregnancy and Lactation: Use is conditional; it is permitted only for the purpose of correcting a diagnosed calcium and Vitamin D deficiency and must adhere to specific maximum daily intake limits set by regulatory authorities.


Restrictions and Precautions

Patients with Impaired Renal Function (mild to moderate), Sarcoidosis, or those who are immobilised due to osteoporosis must use the medicine with caution and require close monitoring of calcium levels, as advised in the official labeling.

Advertisements

What should I know about interactions with other medicines?

This section describes the officially documented interaction patterns for Calciduran Vit. D3 (a fixed combination of Calcium Carbonate and Dihydrotachysterol), structured by pharmacokinetic and pharmacodynamic profiles.

Regulatory documentation advises restrictions on co-administration with other Vitamin D preparations/analogues or other high-dose Calcium supplements. This constraint is necessary due to the combined, additive pharmacodynamic effect, which significantly increases the risk of hypercalcemia and associated adverse events.

The interaction with Thiazide Diuretics is documented to increase the likelihood of hypercalcemia by inhibiting the renal excretion of calcium. Co-administration with Cardiac Glycosides (e.g., Digitalis) is associated with an increased risk of cardiac arrhythmia and ventricular arrhythmias, as hypercalcemia can potentiate the cardiac effects of these drugs.

The calcium component causes pharmacokinetic interference with several medicines. Specifically, Tetracycline Antibiotics and Bisphosphonates (e.g., Alendronate) show significantly reduced systemic exposure when taken concurrently, necessitating a mandatory separation of dosing time to mitigate absorption failure.

Furthermore, the absorption of the Dihydrotachysterol component may be reduced by substances such as Mineral Oil or by foods high in Oxalic or Phytic Acid. Population-specific notes indicate that the hypercalcemia risk with Thiazide Diuretics is heightened for Hypoparathyroid Patients.

Advertisements

Mechanism of Action

Calciduran Vit. D3 (Cholecalciferol) modulates biochemical pathways of mineral homeostasis primarily via the actions of its active metabolite, 1,25-dihydroxyvitamin D3 (Calcitriol).


Nuclear Receptor-Mediated Gene Regulation

This mechanism centers on Calcitriol's role as a transcription factor. Calcitriol binds to the intracellular Vitamin D Receptor (VDR), forming a complex that then binds to specific DNA sequences (VDREs) in target cell nuclei. This molecular mechanism initiates or suppresses gene expression following VDR complex binding, which is essential for systemic effects across various tissues.


Intestinal Mineral Absorption Modulation

Calcitriol’s mechanism modulates pathways associated with the uptake of essential minerals. By upregulating transport proteins, such as calbindin, in the small intestine via VDR activation, Calcitriol enhances the absorption of dietary calcium and phosphate. This results in changes to the fluxes of these minerals between the intestine, bone, and kidney, influencing their respective plasma concentrations.


Parathyroid Hormone (PTH) Regulation

This domain involves engaging mechanisms that influence endocrine feedback regulation. Calcitriol exerts a negative feedback effect directly on the parathyroid glands, suppressing the secretion of PTH. This action decreases circulating PTH, thereby modifying the systemic flux of minerals and bone turnover markers.

Advertisements

Dosage and Administration Information

Standard Administration Guidelines

Administration of Calciduran Vit. D3 is limited to the oral route, utilizing a chewable tablet form. For proper use, the tablet is chewed or sucked before swallowing, rather than being ingested whole.

Dosing and Frequency

The dosing schedule involves a total daily administration of 1000 mg elemental calcium and 800 IU Vitamin D3, which may be delivered by taking a 1000 mg/800 IU tablet once daily or a 500 mg/400 IU tablet twice daily. This schedule is flexible regarding meals, as the tablet may be taken with or without food and drink. If a dose is forgotten, it is not to be compensated for by taking a double amount at the next scheduled time.

Procedural Constraints

A critical procedural constraint is the temporal separation required when co-administering other medicines. For instance, the tablet is administered at least one hour before bisphosphonates and at least four hours before or four hours after levothyroxine due to potential absorption interference. The regimen is generally unchanged for older adults and in cases of hepatic impairment, though use is restricted for individuals with severe renal impairment.

Long-Term Protocol

The medicine is utilized as part of a long-term treatment plan, a context that involves periodic monitoring of serum calcium and renal function as part of the established use protocol.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Calciduran Vit. D3


Evidence for Use in Managing Hypoparathyroidism-Induced Hypocalcemia

Research examines this combination in patients with Hypoparathyroidism and related conditions where the body struggles to maintain stable calcium levels. The available data includes systematic reviews, observational studies, and comparative studies where this formulation was observed against other types of Vitamin D analogues. The focus of these studies included monitoring and recording measurements related to serum calcium and serum phosphorus levels, which are markers for systemic mineral balance.

Findings describe patterns observed in the studies related to the changes in serum calcium measurements in participants using the combination treatment. This research provides insight into short-term changes and monitors how mineral balance was tracked in these groups. What remains uncertain is the full picture of long-term effects. The research so far indicates that detailed data on patient-important clinical outcomes over many years are not well characterized.

Evidence for Use as Adjunctive Treatment for Osteoporosis

The evidence base for using this combination for the management of conditions involving bone mineral density primarily involves Randomized Controlled Trials (RCTs) and meta-analyses. These studies were evaluated in their potential role in conditions affecting bone structure in individuals with Osteoporosis and low bone mineral density. The main outcomes monitored by researchers were physical measures, including changes in Bone Mineral Density (BMD) at sites like the hip and spine, and the overall incidence of nonvertebral fractures.

Studies report how BMD measurements changed in the observed populations during the study period. However, when compared across different trials, findings related to both BMD and fracture outcomes were mixed and varied across populations studied, suggesting that results may apply only to the specific cohorts examined.

Research Gaps and Areas of Uncertainty

Despite the existing research, there are key areas where certainty remains low and further investigation is needed. Evidence regarding the incidence of nonvertebral fractures is often drawn from trials where sample sizes were modest or where the follow-up durations were limited for capturing such events. Additionally, due to the complex nature of the DHT component, the research consistently emphasizes the need for specialized monitoring. Ultimately, studies help show what has been observed so far, but the research does not determine whether an individual will respond similarly.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Calciduran Vit. D3 (FAQ)

Q: Is it okay to take Calciduran Vit. D3 every day?

A: Official administration guidelines describe the use of this medicine as a long-term treatment plan.

The official dosing schedule involves a total daily administration of the specified dose, which is often delivered either once or twice a day. Regulatory documents state that the treatment protocol is designed for sustained, continuous use over an extended period.


Q: Can Calciduran Vit. D3 cause stomach problems or upset digestion?

A: Official regulatory documents acknowledge that the medicine may cause digestive issues.

Gastrointestinal effects such as constipation, flatulence (gas), and nausea are listed as Uncommon side effects in the safety profile.


Q: Can I use Calciduran Vit. D3 if I am already taking another multivitamin?

A: Regulatory documents explicitly warn against using this medicine with other Vitamin D preparations/analogues or other high-dose Calcium supplements.

Patients are advised to check the vitamin D and calcium content of any multivitamin against the official warnings, as this restriction is due to the potential for a combined, additive effect.


Q: What is the expected long-term outcome of using Calciduran Vit. D3 for its approved uses?

A: Studies and official information indicate that this combination is examined for use in managing mineral balance and conditions involving bone density.

Research evidence indicates that data on patient-important clinical outcomes over many years may be limited. Additionally, certainty regarding long-term results for some physical measures, like nonvertebral fractures, remains low and varied across different study groups.


Q: Are there any long-term effects described in official information for Calciduran Vit. D3?

A: Official safety information notes that certain serious adverse reactions are typically linked to long-term use or excessive dosage.

These documented risks include severe Hypercalcaemia (very high blood calcium) and Nephrocalcinosis (calcification in the kidneys), which is why periodic monitoring of calcium levels is an established part of the long-term protocol.


Q: Is Calciduran Vit. D3 considered safe for older adults?

A: The medicine is noted as being for the adult and elderly populations, and the standard regimen is generally unchanged for these groups.

However, the official label highlights the need for routine monitoring of serum and urinary calcium levels for older adults to prevent the documented risks associated with sustained high calcium concentrations.


Q: Why do doctors sometimes recommend Calciduran Vit. D3 instead of just vitamin D?

A: The product contains two active ingredients: calcium and Dihydrotachysterol, a specific synthetic secosteroid that acts as a Vitamin D analogue.

This analogue is chemically modified to be more direct-acting than natural Cholecalciferol (Vitamin D3), meaning it requires fewer metabolic steps to become fully active in the body’s mineral regulation system.


Q: Does Calciduran Vit. D3 contain any common allergens?

A: Official regulatory documents include a full list of all active substances and excipients (inactive ingredients) used in the formulation.

The medicine is contraindicated (should not be used) if you have a known Hypersensitivity to any of these listed ingredients. Patients are required to check this list for the presence of any known allergens or substances of concern.


Q: Can Calciduran Vit. D3 interfere with blood tests?

A: The official use protocol necessitates the periodic monitoring of serum calcium and renal function as part of the established treatment plan.

Since the treatment is designed to modulate mineral balance, it will influence these specific blood parameters, which is why monitoring is required.


Q: Is Calciduran Vit. D3 associated with any known heart issues?

A: Official documentation notes that co-administration with Cardiac Glycosides (a class of heart medication) is associated with an increased risk of cardiac arrhythmia (irregular heartbeat).


Q: Is Calciduran Vit. D3 the same as supplements sold at the pharmacy?

A: The product is classified as a fixed-dose combination oral preparation and an antihypocalcemic agent.

This classification and the inclusion of the synthetic Dihydrotachysterol analogue mark its specific regulatory category.


Q: Are there any dietary supplements that are officially warned against taking with Calciduran Vit. D3?

A: Regulatory documentation specifically advises restrictions on co-administration with other high-dose Calcium supplements or other Vitamin D preparations/analogues.

This is a necessary constraint to avoid the risk of excessive accumulation of calcium and vitamin D in the body.


Q: Is Calciduran Vit. D3 safe for people with a history of liver problems?

A: According to official administration guidelines, the standard treatment regimen is generally unchanged in cases of hepatic impairment (problems with liver function).

Use is officially restricted, however, for individuals with severe renal impairment (kidney problems).


Q: How does the vitamin D component of Calciduran Vit. D3 differ from other forms?

A: The vitamin D component, Dihydrotachysterol, is a synthetic secosteroid that acts as a Vitamin D analogue.

Unlike natural forms of Vitamin D, it is chemically modified to be more direct-acting, meaning it requires fewer steps in the body’s metabolic process to achieve its active form.


Q: Can people who are lactose intolerant take Calciduran Vit. D3?

A: The medicine is contraindicated for patients with a known Hypersensitivity to any excipients (inactive ingredients).

Patients with known intolerances, such as lactose intolerance, should review the excipients list against their dietary restrictions.

Advertisements

How should Calciduran Vit. D3 be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal instructions for this combined calcium and vitamin D product are defined strictly by regulatory labeling to maintain the stability of the active components.

Storage Classification Regulatory Requirement
Temperature Limit Store the medicinal product below mathbf25^circC (for blister-packed tablets).
Protection Store in the original package to protect from light and moisture.
Child Safety Keep out of the sight and reach of children.
Stability Do not use after the expiry date (EXP) printed on the label.
Disposal Rule Dispose of any unused product in accordance with local requirements.

These statements establish the mandatory constraints, dictating that the product requires specific environmental shielding and temperature control to remain viable. The disposal must comply with local pharmaceutical waste guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calciduran Vit. D3 found in:

A-Z Index: